



June 27, 2024

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

Dear Sirs,

Subject: Communication from United States Food and Drug Administration (USFDA)

In terms of Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of Press Release being issued by the Company on the following subject:

“Jubilant Ingrevia Limited successfully receives Establishment Inspection Report (EIR) from USFDA concluded with Zero 483 Inspectional Observations”

The Company has received a communication from USFDA at 11:59 P.M. (IST) on June 26, 2024.

The above mentioned document will be simultaneously posted on the Company's website at www.jubilantingrevia.com.

We request you to take the same on record.

Thanking you

Yours faithfully,
For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657



Jubilant Ingrevia Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubilantingrevia.com

**JUBILANT INGREVIA LIMITED SUCCESSFULLY RECEIVES
ESTABLISHMENT INSPECTION REPORT (EIR) FROM USFDA
CONCLUDED WITH ZERO 483 INSPECTIONAL OBSERVATIONS**

REITERATES COMMITMENT TO HIGHEST STANDARDS OF QUALITY AND COMPLIANCE EXCELLENCE

Noida, Uttar Pradesh, India, June 27, 2024: Jubilant Ingrevia Limited announced successful outcome of the USFDA inspection with the receipt of Establishment Inspection report (EIR) with Zero 483 inspectional observations for the inspection performed in the month of April, 2024 at our Manufacturing facility, Unit -1 located at Bharuch, Gujarat, India.

Speaking on the development, Mr. Deepak Jain, CEO & Managing Director, Jubilant Ingrevia Limited said,

“We are pleased to share that our manufacturing site, Unit-1, intended for the manufacturing of Nutraceuticals & Dietary- Active ingredients for Human consumption in a GMP compliant facility located at Bharuch, Gujarat India has successfully undergone its maiden USFDA inspection with the outcome of zero 483 inspectional observations. This accomplishment reiterates our Company’s unwavering commitment to maintain highest quality and compliance standards. It is also testament to our entire team’s dedication and capability to achieve a common objective that reinforces our leadership position in delivering safe, effective and high-quality compliant products to our customers.”

This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the Company’s strategic capex initiative, shall position Jubilant Ingrevia further to capitalize and mark Company’s foray into regulated market to cater the growing business requirements in the Nutraceuticals, Dietary Active Ingredients, Cosmetic Grade Applications – Active Ingredients, Drug Intermediates, CDMO products intended for industry application and human consumption.



About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The Company has over 2,300 employees and serves more than 1,500 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers. For more information, please visit: www.jubilantingrevia.com.

For more information please contact:

For Investors:

*Pavleen Taneja
Jubilant Ingrevia Limited
Ph: +91-120 436 1000
E-mail: pavleen.taneja@jubl.com*

*Siddharth Rangnekar / Mit Shah
CDR India
Ph: +91 97699 19966 / 99201 68314
E-mail: siddharth@cdr-india.com
mit@cdr-india.com*

For Media & Press:

*Gaurav Jain
Ph: +91 120 436 1026
E-mail: gaurav.jain1@jubl.com*

*Ryan Marshall
Madison Public Relations
Ph: +91 9810047944
E-mail: ryan.marshall@madisonpr.in*

Disclaimer: *Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*
